Jobbet "PhD fellowship in type 1 diabetes – understanding development and early progression of type 1 diabetes." er udløbet
Niels Steensens Vej 2, 2820 GentofteDit næste skridt
A PhD fellowship is available at the Type 1 Diabetes Biology research group at Steno Diabetes Center Copenhagen (SDCC), University of Copenhagen, Denmark.
The position is open for medical doctors with interest in clinical research within the cross field of diabetology and pediatrics. The position is open from May 1st 2018 or as soon as possible thereafter.
SDCC is a hospital specialized in diabetes care, research and prevention and is a part of the Capital Region of Denmark (RegionH)
The PhD study will be a collaborative project carried out at SDCC in Gentofte and Department of Pediatrics at Herlev and Gentofte Hospital under the supervision of Professor Flemming Pociot, SDCC, Head of Systems Medicine Cristina Legido Quigley, and Associate Professor Jesper Johannesen, Herlev and Gentofte Hospital. The PhD will be part of the Department of Type 1 Diabetes Biology at SDCC (headed by Flemming Pociot).
About the project
The aim is to investigate changes in (i) metabolomics and (ii) insulin sensitivity during T1D remission phase in children/adolescents and in adults. The characterization of the remission phase will follow a newly implemented design, e.g. by measuring endogenous insulin production, adding metabolomics and insulin sensitivity (IS) characterization during the first 12 months post-diagnosis. Specifically, the PhD student will work closely together on the remission cohort with another PhD student responsible for the metabolomics research.
This collaborative setup will (i) add new and significant information to the phenotypic characterization and (ii) describe the putative differences during the remission phase in children/adolescents and adults. These new insights may potentially harbor modes of intervention aiming at prolonging the remission phase in children and adults, putatively by different intervention strategies as this research design comprising both children and adolescents most likely will identify different phenotypic characteristics of the T1D remission phase.
What we offer
We offer an exciting multidisciplinary research environment with top-class laboratory and office facilities. A friendly and sociable atmosphere and intercross collaborations and research disciplines are characteristics of SDCC. We have large networks of national and international relations offering great possibilities for synergies with groups outside the house.
The PhD candidate will be offered a full-time position for a period of three years. Employment will be in accordance with the relevant collective agreement within the Capital Region of Denmark.
The candidate must have completed her/his MD. The candidate will preferably have interest in pediatrics and diabetology. Creativity, independent thinking, good communication skills, and the ability to work in a team are all important qualities. The successful candidate will be responsible for the daily management of his/her research project in coordination with the supervisor and other members of the group.
Application & further information
Submit your application including CV, documentation of diplomas (master degree, authorization), names and contact information of 1-2 references no later than 30 April2018. SDCC wishes our staff to reflect the diversity of society and thus welcomes applications from all qualified candidates regardless of personal background. For further information, please contact head of the Type 1 Diabetes Biology group, Professor Flemming Pociot at +45 30 45 63 13.
About Steno Diabetes Center Copenhagen
Steno Diabetes Center Copenhagen is specialized in patient care, research, and prevention of diabetes, and in education of health care professionals within diabetes. SDCC is the biggest diabetes clinic in Scandinavia and treats annually more than 9.000 people with diabetes from the Capital Region of Denmark. For more information visit www.sdcc.dk and follow Steno Diabetes Center Copenhagen on LinkedIn and Twitter.